A Phase 2 interventional study of SAGE-547 in Postpartum Depression, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.
Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 189th largest by enrollment of the 198 interventional ones that give a count, is one of 8 that started in 2015, is one of 18 in phase 2, and was the 63rd registered.
569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.
Browse Depression, Postpartum studies →38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:
University of South Carolina · Sites in United States
Ages 18+ · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
University of Florida · Sites in United States
Ages 15–49 · Women only
Lipocine Inc. · Sites in United States
Ages 15–45 · Women only
Northwestern University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 14 · Phase 4 7
First in 1996; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 104 across 454 interventional studies indexed under Depression, Postpartum.
Median enrollment 86 across the 198 interventional studies, 175 across the 22 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 220 have an industry lead sponsor. The 10 most frequent:
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Supernus Pharmaceuticals, Inc. has 8 studies filed under Depression, Postpartum — fewer than ten, so there is no comparison to draw.
22 of the studies in Depression, Postpartum with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT07822321Phase 3Lipocine Inc.Brexanolone Lifting Outcomes Of Moms | 2027-08 |
| NCT05345834Children's National Research InstituteThe DC Mother-Infant Behavioral Wellness Program | 2026-11-30 |
| NCT06831968University of VirginiaClinical Validation of a Predictive Test for Postpartum Depression | 2026-11-30 |
| NCT06175104Children's Hospital Medical Center, CincinnatiHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 220 studies in Depression, Postpartum with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received SAGE-547 intravenous injection over 60 hours (including 12-hour titration infusion of 21.5 micrograms per kilogram per hour \[mcg/kg/hr\] \[4 hrs\], 43 mcg/kg/hr \[4 hrs\] and 64.5 mcg/kg/hr \[4 hrs\] on Day 1, followed by 13 to 48 hrs \[36 hrs\] maintenance infusion of 86 mcg/kg/hr from Day 1 to 3, followed by a 12-hr taper infusion of 64.5 mcg/kg/hr \[49 - 52 hrs\], 43 mcg/kg/hr \[53 - 56 hrs\] and 21.5 mcg/kg/hr \[57 - 60 hrs\] on Day 3).
Drug: SAGE-547
Intravenous injection
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
AEs were any untoward medical occurrences in a participant who received study treatment without regard to possibility of causal relationship. TEAEs were defined as AEs with onset after the start of SAGE-547 infusion, or any worsening of a pre-existing medical condition or AEs with onset after the start of SAGE-547 infusion and until 7 days after the end of infusion (Day 11). TESAEs were defined as AEs with onset after the start of SAGE-547 infusion, or any worsening of a pre-existing medical condition or AEs with onset after the start of SAGE-547 infusion and until 30 days after the end of infusion (Day 34).
Time frame: TEAEs: Up to Day 11, TESAEs: Up to Day 34
Change From Baseline in Clinical Laboratory Measures: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT)
Clinical laboratory evaluation included: Chemistry (ALT, AST, GGT) expressed in terms of units per liter (U/L). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measures: Carbon Dioxide (CO2), Sodium, Potassium and Chloride
Clinical laboratory evaluation included: Chemistry (carbon dioxide \[CO2\], sodium, potassium and chloride) expressed in terms of millimoles/liter (mmol/L). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measures: Glucose, Total Bilirubin, Calcium, Blood Urea Nitrogen (BUN) and Creatinine
Clinical laboratory evaluation included: Chemistry (glucose, total bilirubin, calcium, blood urea nitrogen \[BUN\] and creatinine) expressed in terms of milligrams/deciliter (mg/dL). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measures: Albumin, Total Protein and Hemoglobin
Clinical laboratory evaluation included: Chemistry (albumin, total protein), Hematology and Coagulation (hemoglobin) expressed in terms of g/dL. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measure: Hematocrit
Clinical laboratory evaluation included: Hematocrit expressed in terms of percentage. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measures: Platelet Count, White Blood Cells (WBC), Absolute Lymphocytes, Absolute Neutrophils, Absolute Basophils, Absolute Eosinophils, Absolute Monocytes
Clinical laboratory evaluation included: Platelet count, white blood cells (WBC), absolute lymphocytes, absolute neutrophils, absolute basophils, absolute eosinophils, absolute monocytes expressed in terms of 10\^9 cells/L. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measure: Red Blood Cells (RBC)
Clinical laboratory evaluation included: RBC expressed in terms of 10\^12 cells/L. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measure: Mean Corpuscular Volume (MCV)
Clinical laboratory evaluation included: MCV expressed in terms of femtoliters (fL). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measure: Mean Corpuscular Hemoglobin (MCH)
Clinical laboratory evaluation included: MCH expressed in terms of picogram (pg). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measure: Prothrombin Time/International Normalized Ratio (PT/INR)
Clinical laboratory evaluation included: PT/INR expressed in terms of seconds. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measure: Potential of Hydrogen (pH)
Clinical laboratory evaluation included: Urinalysis (pH). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Clinical Laboratory Measure: Specific Gravity
Clinical laboratory evaluation included: Urinalysis (specific gravity) expressed in terms of ratio. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Change From Baseline in Vital Sign: Blood Pressure
Vital sign parameters included supine systolic blood pressure (SBP), supine diastolic blood pressure (DBP), standing systolic blood pressure and standing diastolic blood pressure expressed in terms of millimeters of mercury (mmHg). The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).
Time frame: Baseline, Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)
Change From Baseline in Vital Sign: Heart Rate
Vital sign parameter included heart rate expressed in terms of beats per minute (bpm). The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).
Time frame: Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)
Change From Baseline in Vital Sign: Body Temperature
Vital sign parameter included temperature expressed in terms of degree Celsius. The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).
Time frame: Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)
Change From Baseline in Vital Sign: Respiratory Rate
Vital sign parameter included respiratory rate expressed in terms of breaths per minute. The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).
Time frame: Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)
Change From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, PR Interval, QTc Interval, and QRS Duration
ECGs parameters included QT interval, PR interval, QTc interval, QRS duration expressed in terms of milliseconds (msec).
Time frame: Baseline, Day 4 (at 84 hrs)
Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate
ECGs parameter included heart rate expressed in terms of beats per minute (bpm).
Time frame: Baseline, Day 4 (at 84 hrs)
Number of Participants With Physical Examination Findings
Physical examinations included body weight, height, body mass index (BMI) and assessment of body systems (e.g., head, eyes, ears, nose, throat, lungs, abdomen, and extremities) as well as cognitive and mental health examinations (components of the neurological and psychiatric examinations, respectively).
Time frame: At Day 4
Number of Participants With Concomitant Medication Usage
Concomitant medications are other prescription medications, over the counter (OTC) drugs or dietary supplements that a study participant takes in addition to the drug under investigation.
Time frame: Baseline up to Day 11
Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicidal ideation and behavior, and a post-baseline evaluation that focuses on suicidality since the last study visit. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, (with score range from 1 to 5, higher score indicates more severity). The data was collected at time-points: Pre-infusion (Day 1 prior to dosing), Post-infusion (any time after the start of infusion on Day 1 up to 84 hrs).
Time frame: Pre-infusion (Day 1 prior to dosing), Post-infusion (any time after the start of infusion on Day 1 up to 84 hrs)
Maximum Plasma Concentration (Cmax) of SAGE-547
Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose
Time to Maximum Plasma Concentration (Tmax) of SAGE-547
Tmax is defined as the time at which Cmax of SAGE-547 occurred.
Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose
Area Under the Concentration-Time Curve From Start of the Infusion Until the Time of the Last Sample (AUCall) of SAGE-547
AUCall is defined as the area under the plasma SAGE-547 concentration time curves from the start of the infusion until the time the last sample was taken 72 hours later.
Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose
Area Under the Concentration-Time Curve From Time Zero to 60 Hours (AUC0-60) of SAGE-547
AUC0-60 is defined as the area under the plasma SAGE-547 concentration time curve during the intravenous infusion.
Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, and 60 hrs post-dose
Area Under the Concentration-Time Curve in 24 Hours (AUC24) of SAGE-547
AUC24 is defined as the area under the plasma SAGE-547 concentration-time curve in a 24-hour period during the maintenance dose.
Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, and 24 hrs post-dose
Average Drug Concentration in the Plasma at Steady State During a Dosing Interval (Cavg) of SAGE-547
Cavg is defined as the plasma concentration of SAGE-547 at steady-state (average plasma concentration during the maintenance dose period; nominally 12 to 48 hrs).
Time frame: From 12 to 48 hrs (36 hr of maintenance dose period)
Plasma Clearance (CL) of SAGE-547
Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes.
Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose
Change From Baseline in Hamilton Rating Scale for Depression-17 (HAM-D-17) Total Score
The HAM-D-17 was used to rate the severity of depression in participants who were already diagnosed as depressed. The HAM-D-17 is comprised of 17 individual items: Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis, where 0 indicated none/absent and higher scores indicated greater depression. The Total Score can range from 0 (least depression) to 52 (greater depression), and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Time frame: Baseline, Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), Day 3 (at 48 and 60 hrs), and Day 4 (at 84 hrs)
Clinical Global Impression-Improvement (CGI-I) Score
The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I assessment employs a 7-point Likert scale to measure the improvement in the participant's condition. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.
Time frame: Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 84 hrs)
Participants were enrolled in the study at 1 center in the United States from 07 January 2015 to 05 June 2015.
| Milestone | SAGE-547 |
|---|---|
| Started | 4 |
| Completed | 4 |
| Not completed | 0 |
AEs were any untoward medical occurrences in a participant who received study treatment without regard to possibility of causal relationship. TEAEs were defined as AEs with onset after the start of SAGE-547 infusion, or any worsening of a pre-existing medical condition or AEs with onset after the start of SAGE-547 infusion and until 7 days after the end of infusion (Day 11). TESAEs were defined as AEs with onset after the start of SAGE-547 infusion, or any worsening of a pre-existing medical condition or AEs with onset after the start of SAGE-547 infusion and until 30 days after the end of infusion (Day 34).
| Participants | SAGE-547 |
|---|---|
| TEAEs | 4 |
| TESAEs | 0 |
Clinical laboratory evaluation included: Chemistry (ALT, AST, GGT) expressed in terms of units per liter (U/L). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| U/L | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs): ALT | -3.0 ± 4.69 |
| Change From Baseline at Day 3 (48 hrs): ALT | -3.7 ± 7.02 |
| Change From Baseline at Day 4 (84 hrs): ALT | 2.7 ± 2.08 |
| Change From Baseline at Day 2 (24 hrs): AST | -0.5 ± 6.19 |
| Change From Baseline at Day 3 (48 hrs): AST | 1.0 ± 6.24 |
| Change From Baseline at Day 4 (84 hrs): AST | 4.7 ± 5.69 |
| Change From Baseline at Day 2 (24 hrs): GGT | -0.7 ± 2.08 |
| Change From Baseline at Day 3 (48 hrs): GGT | -2.0 ± 1.41 |
| Change From Baseline at Day 4 (84 hrs): GGT | 5.5 ± 9.19 |
Clinical laboratory evaluation included: Chemistry (carbon dioxide \[CO2\], sodium, potassium and chloride) expressed in terms of millimoles/liter (mmol/L). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| mmol/L | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs): CO2 | -0.5 ± 3.42 |
| Change From Baseline at Day 3 (48 hrs): CO2 | -2.0 ± 3.61 |
| Change From Baseline at Day 4 (84 hrs): CO2 | -3.0 ± 4.58 |
| Change From Baseline at Day 2 (24 hrs): Sodium | -0.5 ± 1.00 |
| Change From Baseline at Day 3 (48 hrs): Sodium | -1.3 ± 2.08 |
| Change From Baseline at Day 4 (84 hrs): Sodium | 1.3 ± 2.52 |
| Change From Baseline at Day 2 (24 hrs): Potassium | 0.25 ± 0.208 |
| Change From Baseline at Day 3 (48 hrs): Potassium | 0.20 ± 0.100 |
| Change From Baseline at Day 4 (84 hrs): Potassium | 0.47 ± 0.115 |
| Change From Baseline at Day 2 (24 hrs): Chloride | -0.5 ± 5.00 |
| Change From Baseline at Day 3 (48 hrs): Chloride | -1.3 ± 5.03 |
| Change From Baseline at Day 4 (84 hrs): Chloride | -1.3 ± 6.03 |
Clinical laboratory evaluation included: Chemistry (glucose, total bilirubin, calcium, blood urea nitrogen \[BUN\] and creatinine) expressed in terms of milligrams/deciliter (mg/dL). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| mg/dL | SAGE-547 |
|---|---|
| Change at Day 2 (24 hrs): Glucose | 16.0 ± 15.90 |
| Change at Day 3 (48 hrs): Glucose | 28.3 ± 31.37 |
| Change at Day 4 (84 hrs): Glucose | 17.7 ± 13.58 |
| Change at Day 2 (24 hrs): Total Bilirubin | -0.05 ± 0.129 |
| Change at Day 3 (48 hrs): Total Bilirubin | -0.23 ± 0.153 |
| Change at Day 4 (84 hrs): Total Bilirubin | -0.13 ± 0.115 |
| Change at Day 2 (24 hrs): Calcium | -0.28 ± 0.532 |
| Change at Day 3 (48 hrs): Calcium | -0.03 ± 0.802 |
| Change at Day 4 (84 hrs): Calcium | 0.30 ± 0.265 |
| Change at Day 2 (24 hrs): BUN | 0.5 ± 1.29 |
| Change at Day 3 (48 hrs): BUN | 0.3 ± 4.51 |
| Change at Day 4 (84 hrs): BUN | 0.0 ± 4.58 |
| Change at Day 2 (24 hrs): Creatinine | -0.010 ± 0.0698 |
| Change at Day 3 (48 hrs): Creatinine | -0.050 ± 0.0721 |
| Change at Day 4 (84 hrs): Creatinine | -0.057 ± 0.1159 |
Clinical laboratory evaluation included: Chemistry (albumin, total protein), Hematology and Coagulation (hemoglobin) expressed in terms of g/dL. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| g/dL | SAGE-547 |
|---|---|
| Change at Day 2 (24 hrs): Albumin | -0.40 ± 0.497 |
| Change at Day 3 (48 hrs): Albumin | -0.33 ± 0.551 |
| Change at Day 4 (84 hrs): Albumin | 0.20 ± 0.173 |
| Change at Day 2 (24 hrs): Total Protein | -0.63 ± 0.499 |
| Change at Day 3 (48 hrs): Total Protein | -0.43 ± 0.702 |
| Change at Day 4 (84 hrs): Total Protein | 0.20 ± 0.361 |
| Change at Day 2 (24 hrs): Hemoglobin | 0.02 ± 0.943 |
| Change at Day 3 (48 hrs): Hemoglobin | -0.10 ± 0.954 |
| Change at Day 4 (84 hrs): Hemoglobin | 0.27 ± 0.306 |
Clinical laboratory evaluation included: Hematocrit expressed in terms of percentage. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| percentage of hematocrit | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs) | 0.15 ± 2.199 |
| Change From Baseline at Day 3 (48 hrs) | -1.07 ± 1.914 |
| Change From Baseline at Day 4 (84 hrs) | 1.20 ± 1.311 |
Clinical laboratory evaluation included: Platelet count, white blood cells (WBC), absolute lymphocytes, absolute neutrophils, absolute basophils, absolute eosinophils, absolute monocytes expressed in terms of 10\^9 cells/L. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| 10^9 cells/L | SAGE-547 |
|---|---|
| Change at Day 2 (24 hrs): Platelet Count | -18.8 ± 16.50 |
| Change at Day 3 (48 hrs): Platelet Count | -23.3 ± 27.65 |
| Change at Day 4 (84 hrs): Platelet Count | -4.3 ± 37.98 |
| Change at Day 2 (24 hrs): WBC | -0.93 ± 1.910 |
| Change at Day 3 (48 hrs): WBC | -0.03 ± 3.287 |
| Change at Day 4 (84 hrs): WBC | -1.07 ± 1.069 |
| Change at Day 2 (24 hrs): Absolute Lymphocytes | -0.73 ± 0.764 |
| Change at Day 3 (48 hrs): Absolute Lymphocytes | -0.50 ± 1.273 |
| Change at Day 4 (84 hrs): Absolute Lymphocytes | -0.57 ± 0.737 |
| Change at Day 2 (24 hrs): Absolute Neutrophils | -0.933 ± 0.2082 |
| Change at Day 3 (48 hrs): Absolute Neutrophils | -1.250 ± 0.2121 |
| Change at Day 4 (84 hrs): Absolute Neutrophils | -0.467 ± 0.2082 |
| Change at Day 2 (24 hrs): Absolute Basophils | 0.0 ± 0.00 |
| Change at Day 3 (48 hrs): Absolute Basophils | 0.0 ± 0.00 |
| Change at Day 4 (84 hrs): Absolute Basophils | 0.0 ± 0.00 |
| Change at Day 2 (24 hrs): Absolute Eosinophils | 0.03 ± 0.058 |
| Change at Day 3 (48 hrs): Absolute Eosinophils | 0.05 ± 0.071 |
| Change at Day 4 (84 hrs): Absolute Eosinophils | 0.00 ± 0.100 |
| Change at Day 2 (24 hrs): Absolute Monocytes | -0.10 ± 0.100 |
| Change at Day 3 (48 hrs): Absolute Monocytes | -0.05 ± 0.071 |
| Change at Day 4 (84 hrs): Absolute Monocytes | -0.07 ± 0.058 |
Clinical laboratory evaluation included: RBC expressed in terms of 10\^12 cells/L. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| 10^12 cells/L | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs) | -0.030 ± 0.1924 |
| Change From Baseline at Day 3 (48 hrs) | -0.090 ± 0.2784 |
| Change From Baseline at Day 4 (84 hrs) | 0.113 ± 0.1656 |
Clinical laboratory evaluation included: MCV expressed in terms of femtoliters (fL). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| fL | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs) | 0.85 ± 1.578 |
| Change From Baseline at Day 3 (48 hrs) | -0.53 ± 0.924 |
| Change From Baseline at Day 4 (84 hrs) | 0.33 ± 1.155 |
Clinical laboratory evaluation included: MCH expressed in terms of picogram (pg). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| pg | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs) | -0.3 ± 1.15 |
| Change From Baseline at Day 3 (48 hrs) | 0.5 ± 0.71 |
| Change From Baseline at Day 4 (84 hrs) | -0.3 ± 1.15 |
Clinical laboratory evaluation included: PT/INR expressed in terms of seconds. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| seconds | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs) | -0.30 ± 0.700 |
| Change From Baseline at Day 3 (48 hrs) | -1.05 ± 0.636 |
| Change From Baseline at Day 4 (84 hrs) | -0.37 ± 0.902 |
Clinical laboratory evaluation included: Urinalysis (pH). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| pH | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs) | -0.17 ± 1.155 |
| Change From Baseline at Day 3 (48 hrs) | 0.33 ± 0.289 |
| Change From Baseline at Day 4 (84 hrs) | 1.00 ± 0.000 |
Clinical laboratory evaluation included: Urinalysis (specific gravity) expressed in terms of ratio. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).
| ratio | SAGE-547 |
|---|---|
| Change From Baseline at Day 2 (24 hrs) | -0.0080 ± 0.00458 |
| Change From Baseline at Day 3 (48 hrs) | -0.0017 ± 0.00252 |
| Change From Baseline at Day 4 (84 hrs) | -0.0015 ± 0.00495 |
Vital sign parameters included supine systolic blood pressure (SBP), supine diastolic blood pressure (DBP), standing systolic blood pressure and standing diastolic blood pressure expressed in terms of millimeters of mercury (mmHg). The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).
| mmHg | SAGE-547 |
|---|---|
| Change From Baseline at Day 1 (12 hrs): Supine SBP | -2.8 ± 13.65 |
| Change From Baseline at Day 2 (24 hrs): Supine SBP | 2.3 ± 11.95 |
| Change From Baseline at Day 2 (36 hrs): Supine SBP | -1.0 ± 15.19 |
| Change From Baseline at Day 3 (48 hrs): Supine SBP | -5.0 ± 4.40 |
| Change From Baseline at Day 3 (60 hrs): Supine SBP | 12.3 ± 17.75 |
| Change From Baseline at Day 4 (72 hrs): Supine SBP | 5.0 ± 23.73 |
| Change From Baseline at Day 4 (84 hrs): Supine SBP | 8.0 ± 20.69 |
| Change From Baseline at Day 1 (12 hrs): Supine DBP | -1.3 ± 12.50 |
| Change From Baseline at Day 2 (24 hrs): Supine DBP | 3.0 ± 6.83 |
| Change From Baseline at Day 2 (36 hrs): Supine DBP | -2.3 ± 5.68 |
| Change From Baseline at Day 3 (48 hrs): Supine DBP | -5.0 ± 5.42 |
| Change From Baseline at Day 3 (60 hrs): Supine DBP | 4.0 ± 6.22 |
| Change From Baseline at Day 4 (72 hrs): Supine DBP | 0.5 ± 9.75 |
| Change From Baseline at Day 4 (84 hrs): Supine DBP | 7.5 ± 10.21 |
| Change From Baseline at Day 1(12 hrs):Standing SBP | -4.0 ± 7.87 |
| Change From Baseline at Day 2(24 hrs):Standing SBP | -1.5 ± 8.23 |
| Change From Baseline at Day 2(36 hrs):Standing SBP | -0.8 ± 7.27 |
| Change From Baseline at Day 3(48 hrs):Standing SBP | -1.5 ± 7.68 |
| Change From Baseline at Day 3(60 hrs):Standing SBP | 16.8 ± 2.50 |
| Change From Baseline at Day 4(72 hrs):Standing SBP | 0.3 ± 11.53 |
| Change From Baseline at Day 4(84 hrs):Standing SBP | -0.7 ± 8.74 |
| Change From Baseline at Day 1(12 hrs):Standing DBP | 1.0 ± 8.52 |
| Change From Baseline at Day 2(24 hrs):Standing DBP | 6.3 ± 4.11 |
| Change From Baseline at Day 2(36 hrs):Standing DBP | 1.5 ± 9.11 |
| Change From Baseline at Day 3(48 hrs):Standing DBP | 7.5 ± 5.92 |
| Change From Baseline at Day 3(60 hrs):Standing DBP | 13.8 ± 8.81 |
| Change From Baseline at Day 4(72 hrs):Standing DBP | 13.3 ± 8.14 |
| Change From Baseline at Day 4(84 hrs):Standing DBP | 10.3 ± 3.06 |
Vital sign parameter included heart rate expressed in terms of beats per minute (bpm). The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).
| bpm | SAGE-547 |
|---|---|
| Change From Baseline at Day 1 (12 hrs) | -2.5 ± 15.35 |
| Change From Baseline at Day 2 (24 hrs) | 5.3 ± 18.84 |
| Change From Baseline at Day 2 (36 hrs) | -2.3 ± 11.44 |
| Change From Baseline at Day 3 (48 hrs) | -1.5 ± 11.56 |
| Change From Baseline at Day 3 (60 hrs) | -3.0 ± 8.41 |
| Change From Baseline at Day 4 (72 hrs) | -5.8 ± 7.63 |
| Change From Baseline at Day 4 (84 hrs) | -0.8 ± 4.99 |
Vital sign parameter included temperature expressed in terms of degree Celsius. The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).
| degree Celsius | SAGE-547 |
|---|---|
| Change From Baseline at Day 1 (12 hrs) | -0.20 ± 0.32 |
| Change From Baseline at Day 2 (24 hrs) | 0.15 ± 0.23 |
| Change From Baseline at Day 2 (36 hrs) | -0.15 ± 0.33 |
| Change From Baseline at Day 3 (48 hrs) | -0.05 ± 0.25 |
| Change From Baseline at Day 3 (60 hrs) | 0.03 ± 0.31 |
| Change From Baseline at Day 4 (72 hrs) | -0.30 ± 0.37 |
| Change From Baseline at Day 4 (84 hrs) | -0.45 ± 0.46 |
Vital sign parameter included respiratory rate expressed in terms of breaths per minute. The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).
| breaths/min | SAGE-547 |
|---|---|
| Change From Baseline at Day 1 (12 hrs) | 0.0 ± 1.63 |
| Change From Baseline at Day 2 (24 hrs) | 0.0 ± 2.31 |
| Change From Baseline at Day 2 (36 hrs) | 0.0 ± 2.31 |
| Change From Baseline at Day 3 (48 hrs) | 0.0 ± 4.00 |
| Change From Baseline at Day 3 (60 hrs) | 0.3 ± 1.53 |
| Change From Baseline at Day 4 (72 hrs) | -1.0 ± 1.15 |
| Change From Baseline at Day 4 (84 hrs) | -0.5 ± 1.00 |
ECGs parameters included QT interval, PR interval, QTc interval, QRS duration expressed in terms of milliseconds (msec).
| msec | SAGE-547 |
|---|---|
| Change from Baseline at Day 4 (84 hrs):QT Interval | -28.5 ± 34.31 |
| Change from Baseline at Day 4 (84 hrs):PR Interval | -1.0 ± 9.87 |
| Change from Baseline at Day 4(84 hrs):QTc Interval | 13.3 ± 10.44 |
| Change from Baseline at Day 4(84 hrs):QRS Duration | -3.5 ± 7.19 |
ECGs parameter included heart rate expressed in terms of beats per minute (bpm).
| bpm | SAGE-547 |
|---|---|
| Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate | 14.3 ± 9.29 |
Physical examinations included body weight, height, body mass index (BMI) and assessment of body systems (e.g., head, eyes, ears, nose, throat, lungs, abdomen, and extremities) as well as cognitive and mental health examinations (components of the neurological and psychiatric examinations, respectively).
| Participants | SAGE-547 |
|---|---|
| Number of Participants With Physical Examination Findings | 4 |
Concomitant medications are other prescription medications, over the counter (OTC) drugs or dietary supplements that a study participant takes in addition to the drug under investigation.
| Participants | SAGE-547 |
|---|---|
| Number of Participants With Concomitant Medication Usage | 3 |
C-SSRS scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicidal ideation and behavior, and a post-baseline evaluation that focuses on suicidality since the last study visit. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, (with score range from 1 to 5, higher score indicates more severity). The data was collected at time-points: Pre-infusion (Day 1 prior to dosing), Post-infusion (any time after the start of infusion on Day 1 up to 84 hrs).
| Participants | SAGE-547 |
|---|---|
| Pre-Infusion: Suicidal Ideation | 3 |
| Post-Infusion: Suicidal Ideation | 0 |
| Pre-Infusion: Suicidal Behavior | 1 |
| Post-Infusion: Suicidal Behavior | 0 |
| nanograms per millilter (ng/mL) | SAGE-547 |
|---|---|
| Maximum Plasma Concentration (Cmax) of SAGE-547 | 97.2 ± 77.3 |
Tmax is defined as the time at which Cmax of SAGE-547 occurred.
| hours | SAGE-547 |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) of SAGE-547 | 42 (12 to 48) |
AUCall is defined as the area under the plasma SAGE-547 concentration time curves from the start of the infusion until the time the last sample was taken 72 hours later.
| nanograms*hour per milliliter (ng*hr/mL) | SAGE-547 |
|---|---|
| Area Under the Concentration-Time Curve From Start of the Infusion Until the Time of the Last Sample (AUCall) of SAGE-547 | 3380 ± 1410 |
AUC0-60 is defined as the area under the plasma SAGE-547 concentration time curve during the intravenous infusion.
| ng*hr/mL | SAGE-547 |
|---|---|
| Area Under the Concentration-Time Curve From Time Zero to 60 Hours (AUC0-60) of SAGE-547 | 3160 ± 1360 |
AUC24 is defined as the area under the plasma SAGE-547 concentration-time curve in a 24-hour period during the maintenance dose.
| ng*hr/mL | SAGE-547 |
|---|---|
| Area Under the Concentration-Time Curve in 24 Hours (AUC24) of SAGE-547 | 1590 ± 580 |
Cavg is defined as the plasma concentration of SAGE-547 at steady-state (average plasma concentration during the maintenance dose period; nominally 12 to 48 hrs).
| ng/mL | SAGE-547 |
|---|---|
| Average Drug Concentration in the Plasma at Steady State During a Dosing Interval (Cavg) of SAGE-547 | 66.1 ± 24.1 |
Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes.
| Liters per hour per kilogram (L/hr/kg) | SAGE-547 |
|---|---|
| Plasma Clearance (CL) of SAGE-547 | 1.08 ± 0.22 |
The HAM-D-17 was used to rate the severity of depression in participants who were already diagnosed as depressed. The HAM-D-17 is comprised of 17 individual items: Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis, where 0 indicated none/absent and higher scores indicated greater depression. The Total Score can range from 0 (least depression) to 52 (greater depression), and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| score on a scale | SAGE-547 |
|---|---|
| Change From Baseline at Day 1 (12 hrs) | -21.8 ± 5.50 |
| Change From Baseline at Day 2 (24 hrs) | -23.3 ± 4.19 |
| Change From Baseline at Day 2 (36 hrs) | -24.8 ± 3.59 |
| Change From Baseline at Day 3 (48 hrs) | -24.3 ± 4.99 |
| Change From Baseline at Day 3 (60 hrs) | -24.8 ± 4.19 |
| Change From Baseline at Day 4 (84 hrs) | -21.3 ± 6.85 |
The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I assessment employs a 7-point Likert scale to measure the improvement in the participant's condition. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.
| score on a scale | SAGE-547 |
|---|---|
| Day 1 (12 hrs) | 1.8 ± 0.50 |
| Day 2 (24 hrs) | 1.3 ± 0.50 |
| Day 2 (36 hrs) | 1.0 ± 0.00 |
| Day 3 (48 hrs) | 1.3 ± 0.50 |
| Day 3 (60 hrs) | 1.3 ± 0.50 |
| Day 4 (84 hrs) | 1.5 ± 0.58 |
Collected over AEs: Up to Day 11; SAEs: Up to Day 34. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAGE-547 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | SAGE-547 |
|---|---|
| SedationNervous system disorders | 2/4 |
| Infusion Site DiscomfortGeneral disorders | 1/4 |
| Infusion Site ErythemaGeneral disorders | 1/4 |
| Infusion Site PainGeneral disorders | 1/4 |
| Blood Thyroid Stimulating Hormone IncreasedInvestigations | 1/4 |
| DizzinessNervous system disorders | 1/4 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 1/4 |
| RashSkin and subcutaneous tissue disorders | 1/4 |
| FlushingVascular disorders | 1/4 |
Safety population included all participants who began infusion with SAGE-547 injection.
| Age, Continuous(years) | SAGE-547 |
|---|---|
| Mean | 32.0 ± 6.88 |
| Sex: Female, Male(Participants) | SAGE-547 |
|---|---|
| Female | 4 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | SAGE-547 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 4 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | SAGE-547 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 3 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Ran from Jan 2015 to primary completion in Jun 2015, 4 months.
Results were first posted in Dec 2021, 6 years 5 months after primary completion. A results delay was requested in Apr 2017.
Of 14 phase 2 interventional studies under Depression, Postpartum, half reached primary completion within 17 months of starting (the median); a quarter within 10 and three quarters within 30. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone
Supernus Pharmaceuticals, Inc. →